Spectral Medical Announces Second Quarter Results and Provides Corporate Update

Tigris Trial Enrollment Reaches 126 Patients

Strengthened Balance Sheet with Expected Funds to Complete Tigris Trial Enrollment

TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the second quarter ended June 30, 2024, and provided a corporate update.

Read more at globenewswire.com